ArcheMedX White Paper:

Are Decentralized Clinical Trials at Risk, or Ready? 


50% of clinical trials will be hybrid or decentralized by 2024 according to the latest E&Y Report.

The increasing use of decentralized trial components is incredibly welcome news for our patients, but it also magnifies the operational complexity and risks for trial sponsors.

Check out the latest white paper by the ArcheMedX team and discover if your decentralized clinical trials are at Risk, or Ready.

Learn how to recognize and mitigate the risks when home health staff, caregivers, and patients play more active roles across the study without the same level of oversight and environmental control provided by the PI.

Read more ... register now to download the full report!

Register here to download our white paper . . .